The SERCA-PLN-DWORF axis represents a unifying pathogenic mechanism and a promising therapeutic target across the cardiometabolic disease continuum, including HFpEF and metabolic liver disease.
Answers are grounded in this paper and cite their sources.
Does not support clinical targeting yet; leaves open the SERCA-PLN-DWORF axis for prospective human trials.
Intracellular calcium (Ca 2+ ) homeostasis is a central determinant of cardiometabolic physiology, integrating excitation–contraction coupling, metabolic signaling, and stress adaptation across multiple organs. The sarco/endoplasmic reticulum Ca 2+ -ATPase (SERCA), regulated by the micropeptides phospholamban (PLN) and dwarf open reading frame (DWORF), governs ER/SR Ca 2+ reuptake and thereby shapes Ca 2+ -dependent signaling dynamics. Dysregulation of the SERCA–PLN–DWORF axis is increasingly recognized as a shared pathogenic mechanism in type 2 diabetes–related complications, including diabetic cardiomyopathy and heart failure with preserved ejection fraction (HFpEF), where reduced SERCA2a activity prolongs diastolic Ca 2+ clearance and promotes calcineurin–NFAT activation and mitochondrial Ca 2 ⁺ overload. In the liver, loss of SERCA2b activity promotes chronic ER stress, Ca 2+ –phosphoinositide complex formation, insulin resistance, and fibrotic activation, thereby linking Ca 2+ dysregulation to progressive metabolic liver injury in metabolic dysfunction–associated fatty liver disease (MAFLD) and steatohepatitis (MASH). These observations position Ca 2+ dysregulation as a unifying mechanism across the cardiometabolic disease continuum, spanning myocardial dysfunction, systemic insulin resistance, and progressive fatty liver disease. Therapeutic strategies targeting the SERCA–PLN–DWORF axis, including SERCA activators, PLN-directed antisense oligonucleotides, DWORF gene therapy, and CRISPR-based modulation, have demonstrated efficacy in preclinical models by improving Ca 2 ⁺ handling and alleviating metabolic or contractile stress. Further studies are required to determine the translational feasibility, long-term safety, and optimal patient subsets for SERCA-targeted interventions in cardiometabolic disease.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: